Fused Hexacyclic Imidazole Derivatives as TNFα Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory and autoimmune disorders, neurological and neurodegenerative conditions, pain, cardiovascular issues, metabolic disorders, ocular problems, and oncological diseases lack effective modulators of TNFα activity, particularly due to the absence of fused hexacyclic imidazole derivatives in existing pharmacological agents.
Innovation Solution
Development of fused hexacyclic imidazole derivatives, specifically compounds of formula (IIA) or their N-oxides and pharmaceutically acceptable salts, which act as potent modulators of human TNFα activity, usable in therapies for various disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If macromolecular TNFα inhibitors (antibodies, fusion proteins) are used to treat inflammatory and autoimmune disorders, then TNFα binding to receptors is inhibited, but the treatment options are limited to existing macromolecular classes without novel structural mechanisms
Solution Approach 1:
The patent applies parameter changes by transitioning from macromolecular inhibitors (antibodies, fusion proteins) to small molecule fused hexacyclic imidazole derivatives. This fundamental parameter change in molecular size and structural complexity enables new therapeutic options with different pharmacokinetic and pharmacodynamic properties while maintaining TNFα modulatory activity
Solution Approach 2:
The invention employs composite molecular structures combining fused hexacyclic imidazole cores with various substituent groups (aryl, heteroaryl, alkyl, etc.). This composite approach creates diverse chemical entities that can selectively modulate TNFα activity through different binding interactions, expanding therapeutic versatility beyond single-mechanism macromolecular inhibitors
2Reliability
If existing TNFα inhibitors are used for treating various disorders, then TNFα activity is modulated, but there is a lack of potent modulators with novel chemical structures
Solution Approach 1:
The patent segments the complex problem of TNFα modulation into manageable chemical components: a fused hexacyclic imidazole core structure with systematically varied substituent groups. This segmentation allows for structure-activity relationship studies and optimization of potency while maintaining structural novelty, addressing both effectiveness and innovation requirements
Data Source
AI summary
A series of substituted fused hexacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.